HbO2 Therapeutics is a leader in the development of human and veterinary hemoglobin-based oxygen carriers (HBOCs), therapies that when intravenously administered, increase the oxygen-carrying capacity of blood. The Company has two core products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine), and Oxyglobin® [hemoglobin glutamer - 200 (bovine)] for human and veterinary use, respectively.
In 2001, Hemopure was ap...
HbO2 Therapeutics is a leader in the development of human and veterinary hemoglobin-based oxygen carriers (HBOCs), therapies that when intravenously administered, increase the oxygen-carrying capacity of blood. The Company has two core products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine), and Oxyglobin® [hemoglobin glutamer - 200 (bovine)] for human and veterinary use, respectively.
In 2001, Hemopure was approved in South Africa for the treatment of adult surgical patients who are acutely anemic, for the purpose of eliminating, delaying, or reducing the need for allogeneic red blood cells.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.